Drug Trial Radar · NCT05819684
A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
133
Planned (sponsor's estimate)
Start
Apr 18, 2023
Primary completion
May 30, 2025
Study completion May 30, 2026
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, three-part study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-4602 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects.
Conditions
- Advanced Solid Tumor
Interventions
SHR-4602 for injectionDrug
be administered via intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events (AEs)Time frame: From Day 1 to 90 days after last dose
- Maximum tolerated dose (MTD)Time frame: From Day 1 to 21 days after first dose
- Dose Limiting Toxicities (DLT)Time frame: From Day 1 to 21 days after first dose
- Recommended Phase 2 dose (RP2D)Time frame: From Day 1 to 90 days after last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.